45 results on '"Brodovicz, Kimberly"'
Search Results
2. Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
3. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
4. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study
5. Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database
6. A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
7. Exercise and Vitamin E Intake Are Independently Associated with Metabolic Abnormalities in Human Immunodeficiency Virus-Positive Subjects: A Cross-Sectional Study
8. Sa486 PATIENTS WITH PENETRATING AND/OR STRICTURING CROHN'S DISEASE HAVE A HIGHER REPORTED PREVALENCE OF ACTIVE INTESTINAL AND EXTRA-INTESTINAL SYMPTOMS, SURGERIES AND NEED FOR BIOLOGICS: ANALYSIS OF THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH IBD
9. COMPARATIVE EFFECTIVENESS OF EMPAGLIFLOZIN IN REDUCING TOTAL CARDIOVASCULAR EVENTS IN THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
10. Additional file 1 of Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
11. Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes
12. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure
13. 133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study
14. 134-LB: Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study
15. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
16. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
17. Predictive modeling of hypoglycemia for clinical decision support in evaluating outpatients with diabetes mellitus
18. Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy
19. 249-OR: Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
20. 16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
21. 1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
22. COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
23. Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes
24. Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
25. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
26. Incidence of Chronic Kidney Disease and Progression of Renal Dysfunction in Type 2 Diabetes-The Role of Albuminuria
27. Trends in Type 2 Diabetes Mellitus Complications, Drug Utilization, and Laboratory Outcomes, 2012–2017
28. The Safety of Linagliptin vs. Other Antidiabetic Agents with Regard to the Risk of Heart Failure Hospitalization in Routine Care in the U.S.
29. COMPARATIVE CARDIOVASCULAR SAFETY AND EFFECTIVENESS OF LINAGLIPTIN IN ROUTINE CARE: AN INTERIM ANALYSIS FROM A MONITORING PROGRAM
30. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
31. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review
32. Adherence to treatment guidelines in Type 2 diabetes patients failing metformin monotherapy in a real-world setting
33. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
34. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes.
35. Hepatitis B 1762T/1764A Mutations, Hepatitis C Infection, and Codon 249 p53 Mutations in Hepatocellular Carcinomas from Thailand
36. Fat Redistribution in Indinavir-Treated Patients With HIV Infection: A Review of Postmarketing Cases
37. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.
38. Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema.
39. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
40. Abstract 13655: Healthcare Resource Utilization Among Empagliflozin Initiators With and Without Cardiovascular Disease versus DPP4i in a Commercially-Insured Routine Care Population: An Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
41. Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
42. 1459-P: Comparative Cardiovascular Safety and Effectiveness of Linagliptin in Routine Care: Final Results from a 5-Year Post-Marketing Monitoring Program.
43. Abstract 14741: Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study.
44. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
45. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.